top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


Integrating Teams After M&A or Strategic Partnerships
Value is driven by what happens bringing together individuals and teams In life sciences, mergers, carve‑outs and strategic alliances are now core to how pipelines advance and products reach patients. But while the deal thesis is usually about science, assets and markets, value is delivered (or destroyed) by what happens with people and ways of working in the first 12–18 months. This year has seen so many significant acquisition, across biotech and medtech, a few of the most
sharonshieldsconsu
Nov 126 min read


How AI Is Transforming Clinical Development Drug Discovery Recruitment and Trial Management
Clinical development has always carried a painful contradiction. Science can point to promising biology, yet turning that promise into a tested therapy can take years of trial design, patient matching, site coordination and regulatory work. Many compounds fail late. Many trials struggle to enrol. Many teams spend too much time searching for patterns that sit hidden in papers, scans, genomic files and electronic health records.
sharonshieldsconsu
Oct 239 min read


The Three Things VCs Are Really De‑Risking
Most platform biotechs don’t fail on science—they fail because investors don’t believe the team can turn that science into a real, defensible engine. This post breaks down what VCs are actually trying to de‑risk in a platform biotech, how your first five hires map to those concerns, and the concrete artifacts (org map, hiring plan, scorecards, RA/QA and BD thinking) you can bring to a pitch to show you’re building a fundable team, not just a cool idea.
sharonshieldsconsu
Aug 227 min read


The New Era of Rare Disease Treatment: Highlights From the Last 6 Months
For decades, families affected by rare diseases have heard the same heartbreaking message: ‘There is no approved treatment yet.’ In 2026, that story is finally changing. From the first-ever approval for Menkes disease to a landmark FDA policy shift for gene therapies, the rare disease landscape is transforming at a pace never seen before. Here’s what you need to know.
sharonshieldsconsu
Aug 135 min read
bottom of page